▶ 調査レポート

遺伝子編集薬の世界市場見通し2023年-2029年

• 英文タイトル:Gene Editing Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。遺伝子編集薬の世界市場見通し2023年-2029年 / Gene Editing Drug Market, Global Outlook and Forecast 2023-2029 / MRC2312MG05363資料のイメージです。• レポートコード:MRC2312MG05363
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、111ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥487,500 (USD3,250)▷ お問い合わせ
  Enterprise User¥731,250 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界の遺伝子編集薬市場規模と予測を収録しています。・世界の遺伝子編集薬市場:売上、2018年-2023年、2024年-2029年
・世界の遺伝子編集薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の遺伝子編集薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CRISPR-Cas9遺伝子編集薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

遺伝子編集薬のグローバル主要企業は、CRISPR Therapeutics、 Editas Medicine、 Intellia Therapeutics、 Sangamo Therapeutics、 Bluebird Bio、 Beam Therapeutics、 Yaotang Biotechnology、 ICamuno Biotherapeutics、 Reforgene Medicine、 Star Eyed Creatureなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、遺伝子編集薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の遺伝子編集薬市場:タイプ別、2018年-2023年、2024年-2029年
世界の遺伝子編集薬市場:タイプ別市場シェア、2022年
・CRISPR-Cas9遺伝子編集薬、ジンクフィンガーヌクレアーゼ遺伝子編集薬、その他

世界の遺伝子編集薬市場:用途別、2018年-2023年、2024年-2029年
世界の遺伝子編集薬市場:用途別市場シェア、2022年
・総合病院、専門病院

世界の遺伝子編集薬市場:地域・国別、2018年-2023年、2024年-2029年
世界の遺伝子編集薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における遺伝子編集薬のグローバル売上、2018年-2023年
・主要企業における遺伝子編集薬のグローバル売上シェア、2022年
・主要企業における遺伝子編集薬のグローバル販売量、2018年-2023年
・主要企業における遺伝子編集薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
CRISPR Therapeutics、 Editas Medicine、 Intellia Therapeutics、 Sangamo Therapeutics、 Bluebird Bio、 Beam Therapeutics、 Yaotang Biotechnology、 ICamuno Biotherapeutics、 Reforgene Medicine、 Star Eyed Creature

*************************************************************

・調査・分析レポートの概要
遺伝子編集薬市場の定義
市場セグメント
世界の遺伝子編集薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の遺伝子編集薬市場規模
世界の遺伝子編集薬市場規模:2022年 VS 2029年
世界の遺伝子編集薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの遺伝子編集薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の遺伝子編集薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:CRISPR-Cas9遺伝子編集薬、ジンクフィンガーヌクレアーゼ遺伝子編集薬、その他
遺伝子編集薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:総合病院、専門病院
遺伝子編集薬の用途別グローバル売上・予測

・地域別市場分析
地域別遺伝子編集薬市場規模 2022年と2029年
地域別遺伝子編集薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
CRISPR Therapeutics、 Editas Medicine、 Intellia Therapeutics、 Sangamo Therapeutics、 Bluebird Bio、 Beam Therapeutics、 Yaotang Biotechnology、 ICamuno Biotherapeutics、 Reforgene Medicine、 Star Eyed Creature
...

This research report provides a comprehensive analysis of the Gene Editing Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Gene Editing Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Gene Editing Drug, challenges faced by the industry, and potential opportunities for market players.
The global Gene Editing Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Gene Editing Drug market presents opportunities for various stakeholders, including General Hospital, Specialty Hospital. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Gene Editing Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Gene Editing Drug market was valued at US$ 1187.5 million in 2022 and is projected to reach US$ 3247.1 million by 2029, at a CAGR of 15.6% during the forecast period.
Gene editing drugs are an innovative biomedical treatment method that treat diseases by directly modifying a patient’s genes. These drugs use various gene editing technologies, such as CRISPR-Cas9, ZFN (zinc finger nuclease), to precisely edit the patient’s DNA sequence. Overall, the field of gene-editing drugs has great potential to treat a variety of diseases, but the field will continue to evolve and advance as ethical, safety, and legal issues are addressed.
Key Features:
The research report on the Gene Editing Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Gene Editing Drug market.
Market Overview: The report provides a comprehensive overview of the Gene Editing Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., CRISPR-Cas9 Gene Editing Drugs, Zinc Finger Nuclease Gene Editing Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Gene Editing Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Gene Editing Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Gene Editing Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Gene Editing Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Gene Editing Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Gene Editing Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Gene Editing Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Gene Editing Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Gene Editing Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
CRISPR-Cas9 Gene Editing Drugs
Zinc Finger Nuclease Gene Editing Drugs
Others
Market segment by Application
General Hospital
Specialty Hospital
Global Gene Editing Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Sangamo Therapeutics
Bluebird Bio
Beam Therapeutics
Yaotang Biotechnology
ICamuno Biotherapeutics
Reforgene Medicine
Star Eyed Creature
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Editing Drug, market overview.
Chapter 2: Global Gene Editing Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Gene Editing Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Editing Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Gene Editing Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Gene Editing Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Editing Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Editing Drug Overall Market Size
2.1 Global Gene Editing Drug Market Size: 2022 VS 2029
2.2 Global Gene Editing Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Gene Editing Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Gene Editing Drug Players in Global Market
3.2 Top Global Gene Editing Drug Companies Ranked by Revenue
3.3 Global Gene Editing Drug Revenue by Companies
3.4 Global Gene Editing Drug Sales by Companies
3.5 Global Gene Editing Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Gene Editing Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Gene Editing Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Gene Editing Drug Players in Global Market
3.8.1 List of Global Tier 1 Gene Editing Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Gene Editing Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Gene Editing Drug Market Size Markets, 2022 & 2029
4.1.2 CRISPR-Cas9 Gene Editing Drugs
4.1.3 Zinc Finger Nuclease Gene Editing Drugs
4.1.4 Others
4.2 By Type – Global Gene Editing Drug Revenue & Forecasts
4.2.1 By Type – Global Gene Editing Drug Revenue, 2018-2023
4.2.2 By Type – Global Gene Editing Drug Revenue, 2024-2029
4.2.3 By Type – Global Gene Editing Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Gene Editing Drug Sales & Forecasts
4.3.1 By Type – Global Gene Editing Drug Sales, 2018-2023
4.3.2 By Type – Global Gene Editing Drug Sales, 2024-2029
4.3.3 By Type – Global Gene Editing Drug Sales Market Share, 2018-2029
4.4 By Type – Global Gene Editing Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Gene Editing Drug Market Size, 2022 & 2029
5.1.2 General Hospital
5.1.3 Specialty Hospital
5.2 By Application – Global Gene Editing Drug Revenue & Forecasts
5.2.1 By Application – Global Gene Editing Drug Revenue, 2018-2023
5.2.2 By Application – Global Gene Editing Drug Revenue, 2024-2029
5.2.3 By Application – Global Gene Editing Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Gene Editing Drug Sales & Forecasts
5.3.1 By Application – Global Gene Editing Drug Sales, 2018-2023
5.3.2 By Application – Global Gene Editing Drug Sales, 2024-2029
5.3.3 By Application – Global Gene Editing Drug Sales Market Share, 2018-2029
5.4 By Application – Global Gene Editing Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Gene Editing Drug Market Size, 2022 & 2029
6.2 By Region – Global Gene Editing Drug Revenue & Forecasts
6.2.1 By Region – Global Gene Editing Drug Revenue, 2018-2023
6.2.2 By Region – Global Gene Editing Drug Revenue, 2024-2029
6.2.3 By Region – Global Gene Editing Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Gene Editing Drug Sales & Forecasts
6.3.1 By Region – Global Gene Editing Drug Sales, 2018-2023
6.3.2 By Region – Global Gene Editing Drug Sales, 2024-2029
6.3.3 By Region – Global Gene Editing Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Gene Editing Drug Revenue, 2018-2029
6.4.2 By Country – North America Gene Editing Drug Sales, 2018-2029
6.4.3 US Gene Editing Drug Market Size, 2018-2029
6.4.4 Canada Gene Editing Drug Market Size, 2018-2029
6.4.5 Mexico Gene Editing Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Gene Editing Drug Revenue, 2018-2029
6.5.2 By Country – Europe Gene Editing Drug Sales, 2018-2029
6.5.3 Germany Gene Editing Drug Market Size, 2018-2029
6.5.4 France Gene Editing Drug Market Size, 2018-2029
6.5.5 U.K. Gene Editing Drug Market Size, 2018-2029
6.5.6 Italy Gene Editing Drug Market Size, 2018-2029
6.5.7 Russia Gene Editing Drug Market Size, 2018-2029
6.5.8 Nordic Countries Gene Editing Drug Market Size, 2018-2029
6.5.9 Benelux Gene Editing Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Gene Editing Drug Revenue, 2018-2029
6.6.2 By Region – Asia Gene Editing Drug Sales, 2018-2029
6.6.3 China Gene Editing Drug Market Size, 2018-2029
6.6.4 Japan Gene Editing Drug Market Size, 2018-2029
6.6.5 South Korea Gene Editing Drug Market Size, 2018-2029
6.6.6 Southeast Asia Gene Editing Drug Market Size, 2018-2029
6.6.7 India Gene Editing Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Gene Editing Drug Revenue, 2018-2029
6.7.2 By Country – South America Gene Editing Drug Sales, 2018-2029
6.7.3 Brazil Gene Editing Drug Market Size, 2018-2029
6.7.4 Argentina Gene Editing Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Gene Editing Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Gene Editing Drug Sales, 2018-2029
6.8.3 Turkey Gene Editing Drug Market Size, 2018-2029
6.8.4 Israel Gene Editing Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Gene Editing Drug Market Size, 2018-2029
6.8.6 UAE Gene Editing Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 CRISPR Therapeutics
7.1.1 CRISPR Therapeutics Company Summary
7.1.2 CRISPR Therapeutics Business Overview
7.1.3 CRISPR Therapeutics Gene Editing Drug Major Product Offerings
7.1.4 CRISPR Therapeutics Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.1.5 CRISPR Therapeutics Key News & Latest Developments
7.2 Editas Medicine
7.2.1 Editas Medicine Company Summary
7.2.2 Editas Medicine Business Overview
7.2.3 Editas Medicine Gene Editing Drug Major Product Offerings
7.2.4 Editas Medicine Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.2.5 Editas Medicine Key News & Latest Developments
7.3 Intellia Therapeutics
7.3.1 Intellia Therapeutics Company Summary
7.3.2 Intellia Therapeutics Business Overview
7.3.3 Intellia Therapeutics Gene Editing Drug Major Product Offerings
7.3.4 Intellia Therapeutics Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.3.5 Intellia Therapeutics Key News & Latest Developments
7.4 Sangamo Therapeutics
7.4.1 Sangamo Therapeutics Company Summary
7.4.2 Sangamo Therapeutics Business Overview
7.4.3 Sangamo Therapeutics Gene Editing Drug Major Product Offerings
7.4.4 Sangamo Therapeutics Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.4.5 Sangamo Therapeutics Key News & Latest Developments
7.5 Bluebird Bio
7.5.1 Bluebird Bio Company Summary
7.5.2 Bluebird Bio Business Overview
7.5.3 Bluebird Bio Gene Editing Drug Major Product Offerings
7.5.4 Bluebird Bio Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.5.5 Bluebird Bio Key News & Latest Developments
7.6 Beam Therapeutics
7.6.1 Beam Therapeutics Company Summary
7.6.2 Beam Therapeutics Business Overview
7.6.3 Beam Therapeutics Gene Editing Drug Major Product Offerings
7.6.4 Beam Therapeutics Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.6.5 Beam Therapeutics Key News & Latest Developments
7.7 Yaotang Biotechnology
7.7.1 Yaotang Biotechnology Company Summary
7.7.2 Yaotang Biotechnology Business Overview
7.7.3 Yaotang Biotechnology Gene Editing Drug Major Product Offerings
7.7.4 Yaotang Biotechnology Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.7.5 Yaotang Biotechnology Key News & Latest Developments
7.8 ICamuno Biotherapeutics
7.8.1 ICamuno Biotherapeutics Company Summary
7.8.2 ICamuno Biotherapeutics Business Overview
7.8.3 ICamuno Biotherapeutics Gene Editing Drug Major Product Offerings
7.8.4 ICamuno Biotherapeutics Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.8.5 ICamuno Biotherapeutics Key News & Latest Developments
7.9 Reforgene Medicine
7.9.1 Reforgene Medicine Company Summary
7.9.2 Reforgene Medicine Business Overview
7.9.3 Reforgene Medicine Gene Editing Drug Major Product Offerings
7.9.4 Reforgene Medicine Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.9.5 Reforgene Medicine Key News & Latest Developments
7.10 Star Eyed Creature
7.10.1 Star Eyed Creature Company Summary
7.10.2 Star Eyed Creature Business Overview
7.10.3 Star Eyed Creature Gene Editing Drug Major Product Offerings
7.10.4 Star Eyed Creature Gene Editing Drug Sales and Revenue in Global (2018-2023)
7.10.5 Star Eyed Creature Key News & Latest Developments
8 Global Gene Editing Drug Production Capacity, Analysis
8.1 Global Gene Editing Drug Production Capacity, 2018-2029
8.2 Gene Editing Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Gene Editing Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Gene Editing Drug Supply Chain Analysis
10.1 Gene Editing Drug Industry Value Chain
10.2 Gene Editing Drug Upstream Market
10.3 Gene Editing Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Gene Editing Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



グローバル市場調査レポート販売サイトを運営しているマーケットリサーチセンター株式会社です。